‹ ›
MYP_143432
← PREVIOUS NEXT → BACK
Basic Information
IPB08(SARS-CoV-2-S (1169-1198)-K)
Antimicrobial
Antiviral
Antiviral ▸ Anti-Coronavirus ▸ Anti-SARS-CoV
Antiviral ▸ Anti-Coronavirus ▸ Anti-SARS-CoV-2
Antiviral ▸ Antiviral mechanism ▸ Viral fusion inhibition
Membrane / Ion-channel modulation ▸ Sodium channel modulation ▸ Sodium channel inhibitor
Standard
31 amino acids
C148H257N43O49
Standard
Sequence
ISGINASVVNIQKEIDRLNEVAKNLNESLIK
Physicochemical Analysis
3422.88 Da
6.26
-0.23
-0.45
-0.0075
-0.13
0.70
-0.01
28.37
135.16
0.0000
0.00
0.00
The radar chart summarizes major physicochemical dimensions for quick comparison, while exact numerical values remain listed on the left.
Residue Composition
Amino Acid Composition
Chemical Descriptors
1544.71
-16.71
51.0
49.0
123.0
240.0
0.0
36.0
Structural Visualization
3D PDB MODEL
Drag to rotate. Click a residue or atom to inspect it; the selected residue is highlighted in amber in the current view mode. Use the buttons to zoom.
2D CHEMICAL STRUCTURE
Drag to move
Drag to move. Use the buttons to zoom.
Experimental Records
RECORD: Rec_0000171 VERIFIED: YES
Provenance & Taxonomy
synthetic construct [Synthetic]
32630
Structure & Mods
linear peptide [Linear]
canonical L-amino-acid peptide [L]
None
Chol
Bio-Activity Profile
Antimicrobial Anti-SARS-CoV-2
Vesicular Stomatitis Virus (VSV):inhibition of Pseudovirus (PsV) infection in 293T/ACE2 cells
50 μM
IC50
PMID32376627 Evidence URLhttps://pubmed.ncbi.nlm.nih.gov/32376627/
RECORD: Rec_0047428 VERIFIED: YES
Provenance & Taxonomy
synthetic construct [Synthetic]
HR2 fusion-inhibitory peptide
32630
Structure & Mods
linear peptide [Linear]
noncanonical stereochemical modification [Modified]
None
Chol
Chol
Bio-Activity Profile
Antiviral Anti-VSV Fusion inhibition
Vesicular Stomatitis Virus (VSV) | 293T/ACE2 cells
50 μM
IC50
Mammalian: 20 h; Yeast: 30 min; E. coli: >10 h
PaperDesign of Potent Membrane Fusion Inhibitors against SARS-CoV-2, an Emerging Coronavirus with High Fusogenic Activity. | Zhu Y, Yu D, Yan H, Chong H, He Y. | J Virol. 2020 Jul 1;94(14):e00635-20. | DOI:10.1128/JVI.00635-20 | PMID:32376627 PMID32376627 Evidence URLhttps://pubmed.ncbi.nlm.nih.gov/32376627/
RECORD: Rec_0173066 VERIFIED: YES
Provenance & Taxonomy
Severe acute respiratory syndrome coronavirus 2 [Virus]
HR2-derived fusion inhibitor
2697049
Structure & Mods
linear peptide [Linear]
noncanonical stereochemical modification [Modified]
Lys side-chain cholesterol conjugation
Bio-Activity Profile
Antiviral
Severe acute respiratory syndrome coronavirus 2
1.738 μM
IC50
PaperDesign of potent membrane fusion inhibitors against SARS-CoV-2, an emerging coronavirus with high fusogenic activity PMID32376627 Evidence URLhttps://pubmed.ncbi.nlm.nih.gov/32376627/
RECORD: Rec_0208250 VERIFIED: YES
Provenance & Taxonomy
synthetic construct [Synthetic]
32630
Structure & Mods
linear peptide [Linear]
canonical L-amino-acid peptide [L]
None
Chol
Bio-Activity Profile
Antimicrobial Anti-SARS-CoV-2
SARS-CoV-2:inhibition of cell-cell fusion in 293T/ACE2 cells
4.66±1.565 μM
IC50
PMID32376627 Evidence URLhttps://pubmed.ncbi.nlm.nih.gov/32376627/
RECORD: Rec_0210502 VERIFIED: YES
Provenance & Taxonomy
synthetic construct [Synthetic]
32630
Structure & Mods
linear peptide [Linear]
canonical L-amino-acid peptide [L]
None
Chol
Bio-Activity Profile
Antimicrobial Anti-SARS-CoV-2
inhibition of Pseudovirus (PsV) infection in 293T/ACE2 cells
1.738±0.898 μM
IC50
PMID32376627 Evidence URLhttps://pubmed.ncbi.nlm.nih.gov/32376627/
1 2 3 4 NEXT LAST
Showing 5 records on this page · Page 1 of 4